Madrigal is eying an expansion of Rezdiffra’s capabilities via combination with precision siRNA gene silencing.
Hudson’s ousting follows a recent string of disappointing pipeline results for Sanofi.
The decision by the EC was supported by data from the Myasthenia Gravis Inebilizumab Trial.
The drug price erosion among patent-protected drugs in South Korea may be moderate compared to other major Asia-Pacific (APAC) markets.
Achelous Partners acted as investment banking and financial adviser to Purna during the transaction.
The approvals stem from the Phase III KEYNOTE-B96 trial data, which was presented at the 2025 ESMO Congress.
